Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Privium Fund Management B.V.

Key Points

• Privium Fund Management B.V. increased its holdings in Intellia Therapeutics by 111.9%, owning over 58,000 shares after purchasing an additional 31,000 shares.
• Institutional investors now collectively own 88.77% of Intellia Therapeutics, with notable increases in stakes from firms like Cambridge Investment Research and D.A. Davidson & CO.
• Intellia's recent earnings report showed a loss of ($1.10) EPS, which was better than the expected loss, alongside a revenue of $16.63 million, surpassing consensus estimates.

Privium Fund Management B.V. increased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 111.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,709 shares of the company's stock after purchasing an additional 31,000 shares during the quarter. Privium Fund Management B.V. owned approximately 0.06% of Intellia Therapeutics worth $417,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Harbour Investments Inc. boosted its position in shares of Intellia Therapeutics by 76.7% during the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock worth $37,000 after acquiring an additional 2,264 shares during the last quarter. XTX Topco Ltd grew its position in shares of Intellia Therapeutics by 84.2% during the first quarter. XTX Topco Ltd now owns 80,897 shares of the company's stock valued at $575,000 after purchasing an additional 36,989 shares in the last quarter. GSA Capital Partners LLP increased its holdings in shares of Intellia Therapeutics by 154.7% in the first quarter. GSA Capital Partners LLP now owns 219,918 shares of the company's stock worth $1,564,000 after purchasing an additional 133,577 shares during the last quarter. Corton Capital Inc. purchased a new stake in shares of Intellia Therapeutics in the first quarter worth about $92,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Intellia Therapeutics by 14.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 36,795 shares of the company's stock valued at $262,000 after buying an additional 4,540 shares in the last quarter. Institutional investors own 88.77% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on NTLA shares. Wedbush reissued a "neutral" rating and issued a $7.00 target price on shares of Intellia Therapeutics in a report on Monday, June 16th. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 target price on the stock in a research report on Monday, April 21st. Canaccord Genuity Group reduced their price objective on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a research note on Tuesday, June 3rd. Guggenheim lowered their price objective on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Finally, Citigroup cut their target price on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $33.37.

Intellia Therapeutics Stock Down 2.0%

Shares of NASDAQ NTLA traded down $0.23 during trading hours on Wednesday, hitting $11.35. 3,295,214 shares of the stock were exchanged, compared to its average volume of 4,040,053. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $24.16. The firm has a fifty day moving average price of $10.36 and a 200-day moving average price of $9.48. The company has a market cap of $1.18 billion, a PE ratio of -2.17 and a beta of 2.31.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.16. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The company had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. During the same period in the prior year, the company posted ($1.12) EPS. The firm's quarterly revenue was down 42.6% compared to the same quarter last year. As a group, equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Insider Activity

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 7,462 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the sale, the executive vice president owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. The trade was a 6.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 12,534 shares of company stock worth $153,837 in the last 90 days. Corporate insiders own 3.10% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.